Active Stocks
Mon Mar 04 2024 13:40:48
  1. Tata Steel share price
  2. 153.40 -1.13%
  1. NTPC share price
  2. 355.85 4.10%
  1. Bharti Airtel share price
  2. 1,140.65 0.89%
  1. Larsen & Toubro share price
  2. 3,640.40 -0.38%
  1. Power Grid Corporation Of India share price
  2. 295.25 2.91%
Business News/ Companies / Cipla unit recalls anti-epileptic drug in US over pouch leakage issues
BackBack

Cipla unit recalls anti-epileptic drug in US over pouch leakage issues

Cipla, in a regulatory filing, said InvaGen Pharmaceuticals is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP (500 mg), at the consumer level due to seal integrity issues, allowing for powder leakage from the pouch

Cipla: The medication is used for the treatment of refractory complex partial seizures as adjunctive therapy in patients two years of age and older (Photo: Reuters)Premium
Cipla: The medication is used for the treatment of refractory complex partial seizures as adjunctive therapy in patients two years of age and older (Photo: Reuters)

Drug major Cipla Sunday said its subsidiary is voluntarily recalling one lot of medication in the US due to seal integrity issues.

InvaGen Pharmaceuticals Inc, USA, is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP (500 mg), at the consumer level due to seal integrity issues, allowing for powder leakage from the pouch, the Mumbai-based drug maker said in a regulatory filing.

Also Read | Sebi mulls 'fast track' public issuance of debt securities to increase NIIs participation

An improper seal in the pouch may lead to the leakage of powder blend outside the pouch, resulting in a lower content of medicine inside the pack compared to the label claim and potential underdosing, it added.

The population at risk is primarily infants and young children, Cipla said.

In those patients, there is a reasonable probability that inaccurate dosing might result in a serious adverse effect, such as intoxication or breakthrough seizures, requiring medical intervention, it stated.

Also Read | BJP appoints Vishnu Deo Sai as next Chief Minister of Chhattisgarh

For a small minority of patients, who might have severe or repeated breakthrough seizures, a drop in their phenytoin blood levels could result in life-threatening seizures, requiring immediate emergency room treatment, it said.

Cipla has so far not received any reports of adverse events related to this recall, it said.

The medication is used for the treatment of refractory complex partial seizures as adjunctive therapy in patients two years of age and older who have responded adequately to several alternative treatments.

Also Read | All eyes on Fed, BOE as global rate-cut standoff looms in 2023 policy finale

Vigabatrin for oral solution is not indicated as a first-line agent.

The medication is packaged in foil pouches, each containing 500mg of Vigabatrin, and there are 50 foil-sealed pouches in a shelf pack, Cipla said.

The affected lot was distributed nationwide to partnered distributors and consignees.

Also Read | Dhiraj Sahu IT raids: Recovery amount crosses 300 crore; BJP slams Congress

InvaGen Pharmaceuticals is notifying the customer level through press releases, letters, telefax, telephone, email, and on-site visits and coordinating the return of all recalled products, Cipla noted.

Distributors, retailers and consumers in possession of the affected batch are advised to initiate the return process through their respective place of purchase, it added.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 10 Dec 2023, 06:21 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie